Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
NCT ID: NCT03611738
Last Updated: 2025-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
21 participants
INTERVENTIONAL
2019-02-01
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study rationale is that targeting ALK- and EGFR-negative lung tumors with ceritinib and microtubule inhibitors results in synergistic antitumor effects. Therefore, treatment with ceritinib and docetaxel is a rational combination.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase I Dose Escalation
The design will recruit participants in cohorts of three patients each and will not allow for dose-skipping during escalation. A maximum of 18 participants will be enrolled for the phase I dose escalation. Three ceritinib dose levels have been identified for dose escalation (150 mg, 300 mg, and 450 mg), plus docetaxel at 75 mg. A backup dose (ceritinib 150 mg with docetaxel at 60 mg) is also prepared in case the three dose levels are too toxic. Therefore, four potential dose levels will be used for determination of maximum tolerated dose (MTD). The first cohort will start at dose level 1 (ceritinib 150 mg with docetaxel at 75 mg).
Level -1 Backup Cohort: 150 mg ceritinib; 60 mg/m\^2 docetaxel Level 1 Starting Cohort: 150 mg ceritinib; 75 mg/m\^2 docetaxel Level 2 Cohort: 300 mg ceritinib; 75 mg/m\^2 docetaxel Level 3 Cohort: 450 mg ceritinib; 75 mg/m\^2 docetaxel
Ceritinib
Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.
Docetaxel
Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.
Phase Ib Dose Expansion
Treatment at recommended dose. Investigators plan to have 30 patients for the expansion cohort. This will include participants from the dose escalation portion receiving the recommended dose.
Ceritinib
Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.
Docetaxel
Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ceritinib
Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.
Docetaxel
Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willingness and ability to comply with scheduled study visits and procedures.
* Adult men or women age ≥ 18 years.
* Histologic or cytologic diagnosis of advanced/metastatic Non-small Cell Lung Cancer (NSCLC), stage IIIB/IV.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* 1 - 3 (no more than three) prior regimens for stage IIIB/IV disease, with at least one prior regimen (for any stage) containing a platinum-based agent. One prior PD-1 or PD-L1 antibody-based regimen is allowable and counts as a prior regimen. Prior therapy with a taxane is allowed.
* Participants enrolled on the phase 1b expansion portion of the trial must be willing and able to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 3 months prior to initiation of treatment on Day 1, and must be obtained after most recent tumor progression. Participants for whom newly-obtained samples cannot be provided (e.g., inaccessible or participant safety concern) may submit an archived specimen only upon agreement from the Sponsor.
* Prior radiation is allowed if patients have recovered from side effects.
* Potential participants with a prior history of brain metastases are eligible, provided:
* The brain metastases have been treated
* The patient is asymptomatic from the brain metastases
* Corticosteroids prescribed for the management of brain metastases have been discontinued at least 7 days before registration to study
* The brain metastases are stable on pre-registration imaging
* There is no evidence of leptomeningeal disease
* Measurable metastatic disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
* Life expectancy \> 3 months.
* Must have adequate organ and marrow function.
* Must have adequate laboratory values.
* Participants of child bearing potential must not be pregnant and must use established contraceptive strategies as outlined in the study protocol.
Exclusion Criteria
* Activating mutations in EGFR.
* Potential participants with active malignancies other than NSCLC, or prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers.
* Pregnant or breast feeding.
* Known hypersensitivity to ceritinib, docetaxel, or any of their excipients.
* Serious uncontrolled medical disorder, psychiatric condition or laboratory abnormalities that, in the opinion of the investigator, may increase the risk associated with study participation or may interfere with the interpretation of study results.
* Has had major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure. Video-assisted thoracic surgery (VATS) and mediastinoscopy are exceptions and patients can receive study treatment ≥1 week after these procedures.
* A history of clinically significant noninfectious interstitial pneumonitis (i.e., limiting activities of daily living or requiring therapeutic intervention), including clinically significant radiation pneumonitis.
* Residual toxicity from prior anticancer therapy of grade 3 or greater (CTCAE v5.0), with the exception of alopecia
* Concurrent use of other anticancer approved or investigational agents within 2 weeks of the first dose of study treatment.
* In taxane pretreated patents, any history of dose-limiting toxicity with prior taxane therapy.
* A clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months).
* Uncontrolled diabetes mellitus, defined as fasting plasma glucose \> 200 mg/dL.
* Impaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib, or inability to swallow capsules
* Receiving medications that meet one of the following criteria and that cannot be discontinued at least 1 week prior to the start of treatment with ceritinib and for the duration of participation:
* Medication with a known risk of prolonging QT interval or inducing Torsades de Pointes
* Strong inhibitors or strong inducers of CYP3A4/5 (see Appendix A for list)
* Medications with a low therapeutic index that are primarily metabolized by CYP3A4/5, and/or CYP2C9
* Therapeutic doses of warfarin sodium (Coumadin) or any other coumadin-derived anti-coagulant. Anticoagulants not derived from warfarin are allowed (e.g., dabigatran, rivaroxaban, apixaban)
* Enzyme-inducing anticonvulsive agents
* Herbal medications, including but not limited to: St. John's wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Saltos, M.D.
Role: PRINCIPAL_INVESTIGATOR
H. Lee Moffitt Cancer Center and Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Advent Health Orlando
Orlando, Florida, United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MCC-19656
Identifier Type: -
Identifier Source: org_study_id